Perosphere

About Perosphere

Perosphere Technologies Inc. operates as a private medical technology company with a focus on coagulation diagnostics. Founded in 2011 as Perosphere Inc. by Dr. Sasha H. Bakhru and Dr. Bryan Laulicht, the company emerged as a spin-off from Brown University. Dr. Bakhru, who serves as President and CEO, has a background in biomedical engineering with degrees from Columbia University, Johns Hopkins University, and Carnegie Mellon University. Dr. Laulicht holds a BA in Biophysics from Columbia University and a PhD in Medical Science from Brown University, and was a Postdoctoral Associate in the Harvard-MIT Division of Health Sciences and Technology.

The company's primary offering is the Perosphere ClotChek, a point-of-care (PoC) coagulometer. This handheld, battery-powered device is designed to provide a rapid and comprehensive assessment of a patient's coagulation status using a small sample of whole blood. The ClotChek system delivers results within minutes, enabling healthcare professionals in hospital settings, outpatient clinics, and emergency rooms to make timely decisions regarding diagnosis and treatment, particularly for patients on anticoagulant therapies. The technology is reagent-free and aims to offer lab-like precision at the patient's bedside. The device is CE Marked in the European Union for its Whole Blood Clotting Time (WBCT) assay and the company is pursuing FDA clearance in the United States.

Perosphere Technologies serves hospitals and healthcare professionals, generating revenue through the sale and distribution of its PoC Coagulometer. The company has established distribution agreements in Europe, including with CoRRect Medical GmbH in Germany and M3 Medical in Ireland. The business model is centered on addressing the unmet need for swift and accurate coagulation testing, especially for patients taking Direct Oral Anticoagulants (DOACs), to improve outcomes and reduce healthcare costs. The company has received over $2 million in grants from the National Institutes of Health (NIH) to support the further development and commercialization of its technology.

Initially, Perosphere Inc. developed an anticoagulant reversal agent called ciraparantag (PER977), a small molecule designed to reverse the effects of various anticoagulants, including DOACs and heparins. This pharmaceutical asset was developed under a separate entity, Perosphere Pharmaceuticals Inc., which was acquired by AMAG Pharmaceuticals in 2019. Perosphere Technologies continues as an independent company focused on the diagnostics platform that was developed in conjunction with the reversal agent. The company's estimated annual revenue is approximately $4.6 million.